$20.03
0.03%
Nasdaq, Apr 21, 08:19 pm CET
ISIN
US3723032062
Symbol
GMAB

Genmab - ADR Stock price

$20.04
-0.76 3.65% 1M
-2.92 12.72% 6M
-0.83 3.98% YTD
-8.49 29.76% 1Y
-16.39 44.99% 3Y
-2.94 12.79% 5Y
+12.62 170.08% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.49 2.51%
ISIN
US3723032062
Symbol
GMAB
Sector

Key metrics

Market capitalization $12.32b
Enterprise Value $9.53b
P/E (TTM) P/E ratio 11.32
EV/FCF (TTM) EV/FCF 8.62
EV/Sales (TTM) EV/Sales 3.06
P/S ratio (TTM) P/S ratio 3.95
P/B ratio (TTM) P/B ratio 2.50
Revenue growth (TTM) Revenue growth 30.43%
Revenue (TTM) Revenue $3.12b
EBIT (operating result TTM) EBIT $1.00b
Free Cash Flow (TTM) Free Cash Flow $1.11b
Cash position $2.93b
EPS (TTM) EPS $1.77
P/E forward 13.52
P/S forward 3.42
EV/Sales forward 2.65
Short interest 0.34%
Show more

Is Genmab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Genmab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Genmab - ADR forecast:

17x Buy
65%
8x Hold
31%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a Genmab - ADR forecast:

Buy
65%
Hold
31%
Sell
4%

Financial data from Genmab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
3,120 3,120
30% 30%
100%
- Direct Costs 143 143
-
5%
2,977 2,977
-
95%
- Selling and Administrative Expenses 560 560
17% 17%
18%
- Research and Development Expense 1,413 1,413
28% 28%
45%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,004 1,004
30% 30%
32%
Net Profit 1,132 1,132
79% 79%
36%

In millions USD.

Don't miss a Thing! We will send you all news about Genmab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genmab - ADR Stock News

Positive
Seeking Alpha
6 days ago
Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a cautious approach. The company's robust late-stage pipeline could offset DARZALEX revenue loss with new product launches expected between 2027-2031. Genmab's strong balance sheet with $2.9 billion in cash and no long-term debt provides financial flexibility for R&D and str...
Neutral
GlobeNewsWire
6 days ago
Company Announcement Net sales of DARZALEX ® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 15, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) prod...
Neutral
GlobeNewsWire
7 days ago
Company Announcement COPENHAGEN, Denmark; April 14, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.
More Genmab - ADR News

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today